Duragen onlay and duraseal (on the suture) were used for a dural closure on the posterior cranial fossa.At 10 days, cerebrospinal fluid leak appeared.Surgical intervention was required.The leak was below the graft.The product will not be returned for evaluation.Additional information obtained on 26aug2016 from a non-integra sales representative: it is unknown if the patient has an allergic history.This was a personal remark made by the sales representative.The patient had a fistula repair.In the revision surgery, the leak was sealed with fibrin glue.This was the first time the product was used by the doctor.It was reported that the doctors are aware that this event is expected and they are willing to keep using the products.A conference call was initiated to obtain further information.However, the doctors were unavailable at the time.Request for additional information has been requested from the sales representative and on 13sep2016, the following was provided: duragen onlay 7.5cm x7.5 cm (product id not provided) with lot number 1133190 was used.It was confirmed that duraseal (product id: 206320 duraseal exact spine sealant system) was used on this patient in the cranial area.The csf leak was discovered due to a visible globe observed.Relevant diagnostic and lab tests were requested but the sales representative stated they do not have access to this information.The original surgery when the duragen and duraseal were used and implanted was on (b)(6) 2016.The date of the revision surgery where fibrin glue was used was on (b)(6) 2016.Patient outcome was reported as good.Duragen will not be available to be returned for evaluation.Linked to mfg report numbers: 1121308-2016-00017 (same patient) and 3003418325-2016-00023 (same reporter, similar issue, different patients).
|